04/11/2017

NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Breast Cancer.

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Breast Cancer. These NCCN Guidelines^® are currently available as Version 2.2017.  

• Systemic treatment of recurrent or Stage IV disease (BINV-20)
  • Added ribociclib + letrozole as a category 1 option for postmenopausal patients with no prior endocrine therapy within 1 y.Modified footnote ggg: "Palbociclib or ribociclib in combination with letrozole may be considered in HER2-, metastatic breast cancer."
• Endocrine therapy for recurrent or Stage IV disease (BINV-N)
  • Added “Ribociclib + letrozole (category 1).”
  • Modified footnote 3: Palbociclib or ribociclib in combination with letrozole may be considered as a treatment option for first-line therapy for postmenopausal patients with hormone receptor positive, HER2-negative metastatic breast cancer.
  • Modified footnote 2: “If there is disease progression while on a CDK4/6 inhibitor + letrozole, there are no data to support an additional line of therapy with another palbociclib regimen. Likewise, if there is disease progression while on exemestane + everolimus, there are no data to support an additional line of therapy with another everolimus regimen.”

*For your reference, the previous update (Version 1.2017) to the NCCN Guidelines for Breast Cancer, published on March 10, 2017, is available  here.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium^®, the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.